PDCD1 and hepatocellular carcinoma: However, enrollment of HCC patients with HBV infection showed that low and intermediate HBV-DNA level (<500 IU/mL) did not impact the efficacy and safety of anti-PD-1 therapy [1, 11], even HCC patients with high HBV-DNA level did not show increased incidence of HBV-associated hepatitis [12, 13].